Vivos (RDGL) Capital Expenditures (2010 - 2017)

Vivos (RDGL) posted Capital Expenditures of $2800.0 for Q1 2017, down 71.29% sequentially from $9754.0 in Q1 2013.

Vivos (RDGL) Capital Expenditures (2010 - 2017) Analysis & Trends

Vivos has reported Capital Expenditures for 4 years, with the latest figure at $2800.0 in Q1 2017.

Quarterly Capital Expenditures changed N/A year-over-year to $2800.0 in Q1 2017, while the trailing twelve-month figure through Mar 2017 was -$72124.0 (changed N/A YoY) and the FY2025 annual result came in at $103185.0, changed N/A from the prior year.
Capital Expenditures slipped to $2800.0 in Q1 2017 per RDGL's latest filing, from $9754.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $9754.0 in Q1 2013 and troughed at $2800.0 in Q1 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Abbott Laboratories	199.49 Bn	193.88 Bn	7.27 Bn	497.00 Mn
2	Stryker	127.80 Bn	124.32 Bn	4.50 Bn	202.00 Mn
3	Medtronic	118.98 Bn	109.76 Bn	6.41 Bn	488.00 Mn
4	Boston Scientific	73.58 Bn	73.04 Bn	3.85 Bn	195.00 Mn
5	Edwards Lifesciences	51.93 Bn	47.68 Bn	1.35 Bn	66.90 Mn
6	Dexcom	34.34 Bn	32.39 Bn	830.00 Mn	84.70 Mn
7	GE HealthCare Technologies	33.76 Bn	31.66 Bn	2.18 Bn	100.00 Mn
8	Koninklijke Philips	26.37 Bn	23.05 Bn	4.55 Bn	-74.39 Mn
9	Steris	23.07 Bn	22.59 Bn	684.20 Mn	87.50 Mn
10	Vivos	24.90 Mn	23.34 Mn	-3,105.00	-

Download Data